Information Provided By:
Fly News Breaks for March 6, 2018
AIMT, DBVT
Mar 6, 2018 | 05:37 EDT
Deutsche Bank analyst Andrew Peters is "increasingly bullish" on DBV Technologies' (DBVT) Viaskin Peanut following conversations with allergy practitioners at this year's American Academy of Allergy, Asthma & Immunology meeting. Feedback from expert checks and conversations at the conference are "highly supportive" of the Viaskin Peanut profile, and "sharply contrasted" to the implied clinical and commercial risk at the current stock price, Peters tells investors in a research note. Physicians view both Viaskin Peanut and Aimmune's (AIMT) AR101 as potentially important options for patients, the analyst adds. Peters reiterates a Buy rating on DBV Technologies with a $30 price target.
News For DBVT;AIMT From the Last 2 Days
There are no results for your query DBVT;AIMT